APOKYN Drug Patent Profile

Which patents cover Apokyn, and when can generic versions of Apokyn launch?

Apokyn is a drug marketed by Mdd Us and is included in one NDA.

The generic ingredient in APOKYN is apomorphine hydrochloride. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Apokyn

A generic version of APOKYN was approved as apomorphine hydrochloride by TP ANDA HOLDINGS on February 23^rd, 2022.

Summary for APOKYN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	28
Clinical Trials:	5
Patent Applications:	860
What excipients (inactive ingredients) are in APOKYN?	APOKYN excipients list
DailyMed Link:	APOKYN at DailyMed

Recent Clinical Trials for APOKYN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sunovion	Phase 2
US WorldMeds LLC	Phase 4
ClinData Services, Inc.	Phase 4

See all APOKYN clinical trials

Pharmacology for APOKYN

Drug Class	Dopaminergic Agonist
Mechanism of Action	Dopamine Agonists

US Patents and Regulatory Information for APOKYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mdd Us	APOKYN	apomorphine hydrochloride	INJECTABLE;SUBCUTANEOUS	021264-001	Apr 20, 2004		DISCN	No	No
Mdd Us	APOKYN	apomorphine hydrochloride	INJECTABLE;SUBCUTANEOUS	021264-002	Apr 20, 2004	AP	RX	Yes	Yes

# Apokyn Market Dynamics and Financial Trajectory: Apomorphine Injection Revenue, Competition, Patents, and Generic Risk

Last updated: August 25, 2026

Apokyn is an established U.S. Parkinson's disease rescue therapy containing apomorphine hydrochloride. Its commercial position depends on a narrow but clinically important use: rapid treatment of "off" episodes in patients with advanced Parkinson's disease. The product has limited direct generic competition, but faces structural pressure from alternative rescue therapies, administration complexity, specialty-pharmacy economics, and the aging of its intellectual-property estate.

Supernus Pharmaceuticals markets Apokyn in the United States after acquiring US WorldMeds in 2021. Public filings do not separately report Apokyn revenue in every period, often grouping it with Xadago. That reporting limits drug-specific precision, but the filings show that Apokyn is a mature, relatively small contributor to Supernus' portfolio compared with Oxtellar XR, Trokendi XR and Qelbree.[1]

What is Apokyn and how is it used?

Apokyn is an injectable formulation of apomorphine hydrochloride approved for the acute, intermittent treatment of hypomobility, commonly called "off" episodes, in patients with advanced Parkinson's disease.[2]

Attribute	Apokyn
Active ingredient	Apomorphine hydrochloride
Dosage form	Subcutaneous injection
Primary use	Acute intermittent treatment of Parkinson's "off" episodes
FDA application	NDA 020799
Original U.S. approval	2004
U.S. commercial owner	Supernus Pharmaceuticals
Original U.S. commercial platform	US WorldMeds
Therapeutic category	Parkinson's disease rescue therapy
Administration	Patient or caregiver-administered subcutaneous injection
Principal alternatives	Inbrija, Kynmobi, levodopa adjustments, apomorphine infusion products

Apokyn is not a chronic dopamine-replacement product used continuously throughout the day. It is used when oral levodopa therapy does not provide reliable control and a patient experiences sudden motor deterioration.

When did Apokyn receive FDA approval and what is its regulatory status?

The FDA approved Apokyn in 2004 for intermittent treatment of "off" episodes in advanced Parkinson's disease. The product remains approved and marketed in the United States.[2]

The label requires dose titration and management of clinically significant adverse effects. Apomorphine can cause nausea, vomiting, dizziness, hypotension, somnolence and injection-site reactions. The product is supplied with apomorphine injection and a reusable delivery device rather than as a conventional oral tablet.[2]

What is the Orange Book status of Apokyn?

Apokyn is listed in FDA drug databases under NDA 020799. The product's initial regulatory exclusivity expired many years ago. Any present market protection depends primarily on patents, device-related rights, manufacturing know-how, regulatory barriers and commercial execution rather than new-drug exclusivity.[3]

The practical significance is that a competitor does not need to wait for a current five-year new-chemical-entity exclusivity period to expire. A generic or alternative apomorphine product can pursue an abbreviated pathway if it can satisfy FDA requirements and avoid or challenge relevant patents.

How large is the Apokyn market?

Apokyn addresses a specialized segment of the Parkinson's market. The eligible population is smaller than the population treated with oral levodopa, dopamine agonists or monoamine oxidase-B inhibitors, but treatment can be valuable because "off" episodes can require immediate intervention.

Market demand is shaped by five factors:

1. The number of patients with advanced Parkinson's disease.
2. The frequency and severity of motor "off" episodes.
3. Patient ability to self-administer or rely on a caregiver.
4. Coverage and prior-authorization requirements.
5. Availability of less invasive rescue products.

Apokyn's niche has clinical value but limited volume expansion. The therapy is generally introduced after standard oral treatment has become inadequate, which places it late in the Parkinson's treatment sequence.

How does Apokyn compare with Inbrija and Kynmobi?

Product	Active ingredient	Route	Rescue use	Commercial position
Apokyn	Apomorphine	Subcutaneous injection	Acute "off" episodes	Long-established injectable rescue product
Inbrija	Levodopa	Inhaled powder	Intermittent "off" episodes	Non-injectable alternative
Kynmobi	Apomorphine hydrochloride	Sublingual film	Acute "off" episodes	Direct pharmacologic competitor
Oral levodopa adjustment	Levodopa combinations	Oral	Baseline control and episode management	Main treatment foundation

Inbrija competes through a non-invasive route of administration. Kynmobi was designed to compete more directly with Apokyn by using sublingual apomorphine rather than an injection. The presence of alternatives limits Apokyn's ability to raise price without risking conversion.

Kynmobi's commercial withdrawal in the United States reduced direct competition in the sublingual apomorphine segment. The product's manufacturer, Sunovion, announced U.S. discontinuation in 2023, citing commercial considerations.[4] This improved Apokyn's competitive position within the apomorphine rescue category, although Inbrija and non-device-based treatment strategies remain relevant substitutes.

What is Apokyn's financial trajectory?

Apokyn is a mature product with a relatively stable but constrained revenue profile. Supernus does not consistently disclose standalone Apokyn revenue. In its annual reports, the company has grouped Apokyn and Xadago in commercial disclosures, making drug-specific revenue estimates less reliable than figures for products reported separately.[1]

The financial trajectory has three broad phases:

1. Establishment and specialty-market development

US WorldMeds built Apokyn as a specialty Parkinson's product supported by patient training, dose titration and reimbursement assistance. These services are important because the product's commercial success depends on correct administration and patient persistence, not only prescription volume.

2. Portfolio transition under Supernus

Supernus acquired US WorldMeds in 2021. The transaction expanded Supernus beyond its legacy epilepsy and central-nervous-system products and added Apokyn, Xadago and other commercial assets.[5]

The acquisition gave Supernus:

• An established Parkinson's commercial platform.
• A specialty sales and patient-support infrastructure.
• Additional cash flow from mature branded products.
• Exposure to a therapeutic market different from epilepsy and ADHD.
• Opportunities to use an existing commercial organization across neurology products.

The strategic tradeoff is that Apokyn is mature, has limited label expansion potential and requires costly specialty support.

3. Mature-product pressure

Apokyn's long-term revenue potential is limited by the size of its target population, administration burden and competing rescue therapies. Revenue can remain durable if the company maintains reimbursement access and patient support, but growth is unlikely to resemble that of an early-stage branded medicine.

Supernus' financial exposure to Apokyn is also moderated by portfolio diversification. Even if Apokyn declines, the effect on corporate revenue is smaller than it would be for a single-product company. Conversely, Apokyn is unlikely to become a major corporate growth driver without a new formulation, expanded indication or meaningful international expansion.

What patents protect Apokyn?

Apokyn's original composition-of-matter protection is no longer commercially relevant because apomorphine has been known and used medically for decades. The remaining protection, where applicable, is more likely to involve formulation, delivery devices, dosing methods or manufacturing processes.

Potential protection categories include:

Protection category	Commercial relevance
Apomorphine composition	Weak because the active ingredient is old
Injectable formulation	May address concentration, stability, excipients or packaging
Pen injector	Can create device-specific barriers but may not block all competing dosage forms
Dosing and titration methods	May support method-of-use claims, subject to enforceability
Manufacturing process	Can protect quality, sterility or formulation consistency
Patient-support systems	Commercial barrier rather than patent exclusivity

A patent estate for Apokyn must be assessed against the current FDA Orange Book and the relevant U.S. Patent and Trademark Office records. The presence of a listed patent does not guarantee exclusion of all competing products. A competitor may design around a device or formulation claim, challenge validity, or use a different route of administration.

When does Apokyn lose exclusivity?

Apokyn's FDA new-drug exclusivity expired long ago. The product therefore does not have a current statutory exclusivity period comparable to a recently approved new chemical entity.

The relevant loss-of-exclusivity question is instead whether a competitor can obtain approval for:

• A generic apomorphine injection.
• A competing injector or cartridge.
• A different apomorphine dosage form.
• A non-infringing formulation.
• A therapeutically substitutable Parkinson's rescue product.

The absence of current NCE exclusivity increases theoretical generic risk. Actual entry remains difficult because injectable products require sterile manufacturing, device compatibility, pharmacokinetic comparability where applicable, and dependable supply.

What generic entry risks exist for Apokyn?

Generic entry risk is moderate rather than immediate and binary.

Regulatory barriers

An injectable generic must demonstrate pharmaceutical equivalence and meet FDA quality requirements. The manufacturer must address sterility, stability, container closure, dose delivery and device performance. If the reference product uses a specialized pen, a competitor may need to replicate the delivery system or establish a legally and clinically acceptable alternative.

Commercial barriers

Apokyn is supported by specialized patient education and titration. A generic supplier would need to reproduce enough of that infrastructure to convert patients. Physicians may also avoid switching stable patients who have learned a specific administration process.

Pricing barriers

A generic could pressure price, but the market may not behave like a high-volume oral generic market. A small Parkinson's rescue population and complex delivery requirements can reduce the incentive for multiple entrants.

Litigation and Paragraph IV exposure

A Paragraph IV challenge could arise if a generic applicant certifies that an Orange Book-listed patent is invalid, unenforceable or not infringed. Publicly available information does not establish a major current Apokyn Paragraph IV litigation campaign comparable with those involving high-revenue mass-market drugs.

The more probable entry route is a formulation or device-specific challenge by a focused specialty manufacturer rather than a broad wave of conventional tablet generics.

Which companies challenge Apokyn commercially?

Apokyn's competitive set includes:

• Acorda Therapeutics, through Inbrija.
• Sunovion, historically through Kynmobi before U.S. discontinuation.
• Manufacturers of levodopa-based oral rescue and extended-release regimens.
• Developers of continuous subcutaneous or wearable apomorphine delivery systems.
• Future generic or specialty injectable manufacturers.

The competitive threat is broader than direct molecule-to-molecule substitution. Physicians may choose a different rescue route to avoid injections, reduce nausea, simplify administration or improve patient acceptance.

How strong is the Apokyn patent estate?

Apokyn's patent position is best characterized as mature and product-specific, not foundational.

Its strengths are:

• Established FDA approval.
• Physician familiarity.
• Patient training infrastructure.
• A specialized injector and treatment workflow.
• Manufacturing and quality-control requirements.

Its weaknesses are:

• Old active ingredient.
• Expired original regulatory exclusivity.
• Limited ability to block alternative routes.
• Potential design-around options.
• Dependence on a narrow patient population.

Device and formulation patents can delay or complicate entry, but they rarely provide the breadth of a valid, unexpired composition patent. The commercial moat is therefore a combination of regulatory execution, patient persistence, reimbursement access and manufacturing reliability.

What manufacturing and intellectual-property barriers affect Apokyn?

Apokyn requires sterile injectable production and a reliable delivery device. Those requirements create meaningful operational barriers.

Manufacturers must control:

• Sterility assurance.
• Apomorphine stability.
• Container and injector compatibility.
• Dose accuracy.
• Packaging and cold-chain or storage requirements, where applicable.
• Consistent supply of specialized components.
• Adverse-event monitoring and patient-support logistics.

These barriers can discourage entry even after formal patent protection weakens. They also expose the product to supply interruptions that could shift patients to competing rescue therapies.

What licensing deals and ownership changes affect Apokyn?

US WorldMeds commercialized Apokyn in the United States before Supernus acquired US WorldMeds. Supernus completed the acquisition in 2021, bringing Apokyn and other US WorldMeds assets into its neurology portfolio.[5]

Apomorphine itself has a wider international commercial history, with rights and products held by different companies across jurisdictions. U.S. ownership does not establish worldwide control of apomorphine rights. Geographic analysis must distinguish:

• U.S. Apokyn commercialization.
• European apomorphine infusion products.
• Regional rights held by licensors or distributors.
• Device and formulation rights separate from the active ingredient.

What generic launch scenarios are most likely for Apokyn?

Scenario 1: No near-term generic entry

Supernus retains the market through patient-support programs, reimbursement management and reliable supply. Apokyn revenue declines gradually as the treated population ages and physicians adopt alternatives.

Scenario 2: One specialty injectable entrant

A single manufacturer launches an approved generic or alternative injector. Price erosion is meaningful but less severe than in a high-volume oral market because of training and device complexity.

Scenario 3: Device-led substitution

A competitor launches a more convenient apomorphine delivery system without directly replicating the Apokyn pen. The market shifts through clinical preference rather than formal generic substitution.

Scenario 4: Continued erosion from non-injectable rescue therapy

Inbrija or future inhaled, sublingual or other non-injectable products gain use among patients unwilling or unable to administer injections. This scenario can reduce Apokyn volume even without generic competition.

What is the outlook for Apokyn revenue and market value?

Apokyn is likely to remain a cash-generating mature neurology asset rather than a high-growth product. Its near-term value depends on retention of existing patients, payer coverage and the absence of a well-supported competing injectable.

The main upside drivers are:

• Reduced direct competition after Kynmobi's U.S. withdrawal.
• Growth in the advanced Parkinson's population.
• Improved injector usability.
• Better nausea management and titration support.
• Broader reimbursement coverage.
• International licensing or distribution expansion.

The main downside drivers are:

• Generic or device-based entry.
• Migration to non-injectable rescue products.
• High patient discontinuation caused by adverse effects or administration difficulty.
• Payer pressure on specialty-drug pricing.
• Manufacturing disruption.
• Limited new-indication opportunities.

Key Takeaways

• Apokyn is an FDA-approved apomorphine injection for intermittent Parkinson's "off" episodes.
• The product is a mature branded therapy with no meaningful remaining new-chemical-entity exclusivity.
• Supernus owns the U.S. commercial business after acquiring US WorldMeds in 2021.
• Supernus has not consistently disclosed standalone Apokyn revenue, limiting precise drug-level financial modeling.
• Apokyn's commercial protection rests more on patient support, device know-how, manufacturing complexity and physician familiarity than on broad composition patents.
• Kynmobi's U.S. discontinuation reduced direct sublingual apomorphine competition.
• Inbrija and other non-injectable rescue approaches remain important competitive threats.
• Generic risk is moderate because sterile injectable and device requirements raise entry costs, but the old active ingredient and expired regulatory exclusivity leave the product exposed.
• The likely financial trajectory is stable-to-declining mature-product revenue unless Supernus improves delivery, expands access or adds commercial rights in new markets.

FAQs About Apokyn Market Dynamics and Exclusivity

Is Apokyn still commercially available in the United States?

Yes. Apokyn remains an FDA-approved and marketed treatment for intermittent "off" episodes in advanced Parkinson's disease.

Does Apokyn have a composition-of-matter patent?

The active ingredient, apomorphine, is an old compound. Current commercial protection, if any, is more likely to involve formulation, injector, dosing or manufacturing claims.

Is Apokyn interchangeable with Inbrija?

No. Apokyn is a subcutaneous apomorphine injection, while Inbrija is inhaled levodopa. They have different active ingredients, administration routes and prescribing considerations.

Why can Apokyn remain valuable after patent exclusivity ends?

Specialized administration, patient titration, sterile manufacturing, device requirements and reimbursement infrastructure can delay or limit practical competition after formal exclusivity expires.

Did Kynmobi's withdrawal eliminate competition for Apokyn?

No. It removed a direct sublingual apomorphine competitor in the U.S., but Inbrija, oral treatment strategies and emerging delivery systems continue to compete for Parkinson's rescue-therapy use.

References

1. Supernus Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.

2. U.S. Food and Drug Administration. (2023). Apokyn prescribing information. FDA.

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Apokyn, NDA 020799. FDA.

4. Sunovion Pharmaceuticals Inc. (2023). Kynmobi U.S. commercial discontinuation announcement. Sunovion Pharmaceuticals.

5. Supernus Pharmaceuticals, Inc. (2021). Supernus Pharmaceuticals completes acquisition of US WorldMeds. Supernus Pharmaceuticals.